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Abstract
Background: Prevalence of osteoarthritis (OA) is on rise on the global scale. At present there are no satisfactory
pharmacological agents for treating OA. Our previous study showed that Sida cordifolia L. and Zingiber officinale
Rosc. had protective effect on cartilage. Here, we describe the effect of OA-F2, a herbal formulation prepared using
combination of these two plants in alleviating OA associated symptoms in a rat model of collagenase-induced OA.
Methods: OA was induced by intra-articular injection of collagenase type II in wistar rats. Diclofenac (10 mg/kg)
was used as a reference control. Rats (n = 6) were divided into 6 groups: Healthy control (HC), osteoarthritic control
(OAC), diclofenac (DICLO), OA-F2L (135 mg/kg), OA-F2M (270 mg/kg) and OA-F2H (540 mg/kg). The effects of the
20 days treatment were monitored by parameters like knee diameter, paw volume, paw retraction; serum C-reactive
protein (CRP), alkaline phosphatase (ALP) and glycosaminoglycan (GAG). Radiography and histopathology of knee
joint were also studied. Additionally, gene expression was studied from isolated synovium tissue proving anti-
osteoarthritic potential of OA-F2.
Results: Oral administration of OA-F2 has significantly prevented knee swelling compared to OAC; OA-F2 and
DICLO, significantly reduced paw volume compared to OAC. Paw latency was remarkably increased by OA-F2
compared to OAC. OA-F2L (−0.670, p < 0.001), M (−0.110, p < 0.05) and H (0.073) has markedly reduced levels of CRP
compared to DICLO. OA-F2L (p < 0.05), M (p < 0.001) and H (p < 0.05) significantly reduced ALP levels, compared to
DICLO. GAG release in the serum was also significantly lowered in OA-F2 treated group compared to DICLO.
Radiological and histopathological observations showed cartilage protection by OA-F2. OA-F2 has upregulated SOD
and GPx. Upregulated CAT expression was observed in OA-F2M and H. Considerable down-regulation of expression
of MMP-3 and MMP-9 was observed in all the groups. Up-regulation of TIMP-1 was observed in rats treated with
OA-F2L, H and DICLO.
Conclusion: OA-F2 has shown therapeutic effects in rat model of collagenase induced OA by demonstrating
cartilage protection through controlling MMPs and improving anti-oxidant levels in arthritic synovium and is a
potent candidate for further drug development and treatment for OA.
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Background
Osteoarthritis (OA) is a complex multifactorial disease
of whole joint [1]. Pathological loss of cartilage re-
flects the imbalance between catabolic and anabolic
mechanism of cartilage remodeling, which is influ-
enced by oxidative and inflammatory changes in the
surrounding tissues especially synovium and subchon-
dral bone. The prevalence of OA in Indian population
is estimated to be 22–39%; it is a major cause of joint
pain and disability in aging population imposing a
high social burden [2–4]. However, mechanism in-
volved behind this degenerative disease is poorly
understood that reflects in the current lack of effect-
ive medical therapies [5].
The cascade starting from reactive oxygen species
(ROS) leading to inflammation and increased matrix
metalloproteinases are the important factors of deg-
radation of matrix components [6]. They have been
found to be overproduced in OA cartilage and syno-
vium [6]. Previous reports have shown that, ROS
scavengers can slow-down cartilage loss [6]. ROS con-
tribute to cartilage degradation by sustaining the ac-
tivity of catabolic cytokines and by reducing cartilage
repair capacities. When ROS production exceeds the
antioxidant capacities of the cell, an “oxidative stress”
occurs that contributes to structural and functional
cartilage damages. Oxidative stress is found to be ele-
vated in cartilage and synovial tissues, which contrib-
utes to disease progression by increasing production
of inflammatory mediators and matrix degrading en-
zymes [7]. To prevent toxicity by ROS, chondrocytes
express a well co-ordinated anti-oxidant enzyme sys-
tem in the form of SOD, CAT and GPX [6]. Matrix
metalloproteinases (MMPs), which contribute to the
accelerated degradation of extracellular matrix and
tissue inhibitors of metalloproteinases (TIMPs) that
regulates the MMP activity, play an important func-
tion in cartilage matrix turnover [8]. However, in OA
affected joint tissues, up-regulation of MMPs is re-
ported higher compared to TIMPs [8]. Altogether,
these observations support the concept of antioxidant
therapy along with modulation of MMP-TIMP might
also decrease the progression of OA.
Unfortunately, at present there is no medicine or
therapy that can target cartilage protection. Conse-
quently, there is a growing interest in complementary
and alternative medicines (CAM) either in the form
of nutraceuticals or in the form of herbals that pri-
marily thought to be chondroprotective and may even
repair cartilage. It is therefore interesting to explore
traditional systems of medicine for a potential drug
that may help to reduce inflammation, protect cartil-
age damage, improve joint functions and restore pa-
tient’s activity levels.
In our earlier studies, anti-osteoarthritic potential of
six herbs was shown, which are commonly used by
Ayurvedic physicians for the treatment of OA viz.
Sida cordifolia L., Piper longum L., Zingiber officinale
Rosc., Ricinus communis L., Vitex negundo L. and Tri-
bulus terrestris L., in collagenase type II induced OA
(CIOA) rat model [9]. Sida cordifolia L. has been
proven to be effective in balancing Vata dosha, which
is one of the basic principals in Ayurveda [10]. S. cor-
difolia is shown to inhibit cyclooxygenase (COX)
leading to the inhibition of prostaglandin (PGE) syn-
thesis [11]. Zingiber officinale Rosc. is a common
spice with several ethnomedicinal and nutritional
values. It has been used traditionally for treating arth-
ritic conditions [12]. It decreases interleukin-1 (IL1),
nitric oxide (NO) and PGE2 and inhibit leukotriene
B4 (LTB4) production in osteoarthritic cartilage [11, 13], it
also inhibit production of tumor necrosis factor-α (TNF-
α) in human osteoarthritic synoviocytes and chondrocytes
[14]. Srivastsava et al. [15] reported 6-gingerol, active
compound from its rhizome inhibit nuclear factor kappa
B (NF-κB), activator protein-1 (AP-1), TNF-α, interleukin
12 (IL12), inducible NO synthase and COX-2 [16]. Z. offi-
cinale inhibits biotransformation of arachidonic acid into
inflammatory prostaglandin. In a clinical study on knee
OA, using formulation containing Z. officinale as one of
its ingredients, there was significant reduction in pain
score [17].
In the present study, a novel herbal formulation
named as OA-F2 was designed comprising a propor-
tionate combination of S. cordifolia and Z. officinale,
these herbs have shown appreciable anti-osteoarthritic
potential in our previous studies [9]. We have studied
efficacy of oral administration of OA-F2 in alleviating
OA associated symptoms by using collagenase-




Roots of S. cordifolia and rhizomes of Z. officinale were
obtained from Green Pharmacy (Pune, Maharashtra,
India) in dried form. The drugs were then identified and
authenticated in house by Ayurvedic experts using API
parameters viz. total ash, acid insoluble ash, alcohol
soluble extractive, water soluble extractive and pH of
extract.
The composition
Roots of S. cordifolia and rhizomes of Z. officinale were
obtained, they were shade dried. The composition ma-
terial of OA-F2 was prepared by blending powders of S.
cordifolia roots and Z. officinale rhizomes, with 1 : 1
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ratio and given in their powder form after sieving
through mesh No.120.
Experimental animals
Institutional animal ethics committee approval for the
experimental protocol was obtained from Bharati
Vidyapeeth Deemed University, Medical College,
Pune, before initiation of the study (BVDUMC/
CPCSEA/2679/2012-13). Female wistar rats (n = 36)
weighing between 180 and 300 gm were used for the
experiment. They were housed for two weeks in solid
bottomed polypropylene cages for acclimatization be-
fore use, maintained under standard conditions and
fed standard rat chaw with water ad libitum. Guide-
lines laid down by the CPCSEA were observed
throughout the study for animal handling and
experimentation.
Treatment
Rats were obtained from National Institute of Biosci-
ences (Pune, India) and divided into 6 groups of 6
animals each. Group I (HC) animals served as a con-
trol (Received normal sterile saline injection 50 μl
intra-articularly to the right knee). All other groups
were injected 50 unit of collagenase type II intra-
articularly to right knee. Group II (OAC) was main-
tained as osteoarthritic control and were not given
any treatment, Group III (DICLO) was positive con-
trol, given standard drug diclofenac (10 mg/kg p.o);
Group IV (OA-F2L) served with test drug OA-F2 at
the dose of 135 mg/kg b. wt., Group V (OA-F2M)
served with test drug OA-F2 at the dose of 270 mg/
kg b. wt., Group VI (OA-F2H) served with test drug
OA-F2 at the dose of 540 mg/kg b. wt.
Collagenase type II-induced osteoarthritis (CIOA)
Rats were anesthetized with diethyl ether (Merck,
India). Right knee joints were shaved. Group I were
injected with 50 μl of normal saline solution and
served as control. Animals from the second group
were intra-articularly injected with 50 μl collagenase
type II (Sigma Aldrich, USA) dissolved in saline (50
unit) into the right knee joint [9, 18]. The injection
was performed on 1st and 4th day of the experiment
[19]. Standard drug diclofenac (Manufactured by
Medreich Limited, India) was given at the dose of
10 mg/kg b. wt. in 0.5% sodium-carboxy methyl cellu-
lose, based on previous reports [20]. The formulation
doses were selected based on the human dose men-
tioned in the Ayurvedic literature and was calculated
for animal use based on the body surface area ratio
[21]. Doses were administered as oral suspension in
water, once per day by feeding needles from day 14
to 34.
Effect of OA-F2 on Knee diameter, Paw volume and Paw
latency in CIOA rats
Knee diameter was measured on 0th, 5th, 10th, 15th,
20th, 25th and 30th day using digital vernier caliper
(Mitutoyo, Japan), mean changes in joint swelling after
treatment were calculated. Paw volume was measured
once in a week using digital plethysmometer (Orchid
Scientifics, India) and % Inhibition of paw edema with
respect to OAC group was calculated using following
formula: Percent inhibition of paw edema = (Vc-Vt)/
Vc*100, Where Vc: Paw Volume of OAC group, Vt: Paw
Volume of test group. Paw latency measured before and
after treatment using tail flick unit (Ugobasile unit,
Italy), Paw latency after treatment was determined.
Determination of markers from serum
Blood was removed before and after treatment through
retro-orbital vein puncture and serum was separated.
C-reactive protein (CRP) was determined using quan-
titative turbidometric test. Alkaline phosphatase (ALP)
activity was determined using Mod. Kind and King’s
method (Coral clinical systems, Tulip group, India).
Glycosaminoglycans (GAG) assay was performed as
described in Hoemann et al. [22].
Radiological analysis
Before the termination of experiment, the animals were
anesthetized using diethyl ether and anterioposterior
(AP) X-rays using (GE Medical Systems- DXD 300,
300MA, America) thermal laser AGFA digital photo
films (digitizer CR-30, AGFA photo film, Belgium) were
taken for the knee joints of the animals to evaluate the
cartilage degradation and joint space reduction. The
X-ray was operated at 300 MA, 50 KV, 0.02 s expo-
sure time and a 100 cm tube to film distance for AP
projection.
Histopathological analysis
On day 34th, animals were sacrificed, the right knee
joint was dissected and fixed in 10% phosphate buffered
formalin and were decalcified, sectioned and finally
stained with hematoxyline and eosin (H and E),
safranin-O and masson’s trichome. Synovium was dis-
sected out and fixed in 10% phosphate buffered formalin
for staining. Tissue samples were prepared for light
microscopy using standard procedures.
Quantitative real-time reverse transcription-polymerase
chain reaction (qPCR) analysis
Animals were sacrificed at the end of the experiment
and their synovial tissue was removed, flash frozen
immediately in liquid nitrogen, stored at −80 °C and
subsequently used for quantitative real-time reverse
transcription-polymerase chain reaction (qPCR) studies.
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Total RNA from isolated knee synovium tissue was ex-
tracted using TRIZOL reagent (Sigma Aldrich, USA)
with PureLink RNA mini kit (Invitrogen CA, USA).
Quality of the isolated RNA was determined using de-
naturing agarose gel electrophoresis followed by quanti-
fication by measuring absorbance at 260 nm. The first
strand cDNA was synthesized from 1 μg of total RNA
using the SuperScript first-strand synthesis system for
quantitative real-time PCR (Applied Biosystems CA,
USA). qPCR analysis was performed with the help of a
StepOne realtime PCR system (Applied Biosystems, CA,
USA) using TaqMan gene expression assays (Applied
Biosystems, CA, USA). Taqman gene expression master
mix was procured from Applied Biosystems (CA, USA).
Cycling conditions were 50 °C for 2 min; 95 °C for
10 min; and 40 cycles of 95 °C for 15 s, 60 °C for 1 min.
The Taqman gene expression assays that were used in
this study are SOD (Sod1; Rn00566938_m1), GPx
(Gpx1; Rn00577994_g1), CAT (Cat; Rn00560930_m1),
MMP-3 (Mmp3; Rn00591740_m1), MMP-9 (Mmp9
Rn00579162_m1) and TIMP-1 (Timp1; 1 Rn00587
558_m1). The data was analyzed using Data Assist
software version 3.0. The data is representative of syno-
vium from at least three animals. The relative abundance
of the RNA was calculated to the amount of β-actin
(Actb; Rn00667869_m1) using StepOne software version
2.2.2, DataAssist version 3.0 (Applied Biosystems, CA,
USA) and the ΔΔ Ct method [23].
Statistical analysis
Statistical analysis was carried out by one-way analysis
of variance (ANOVA) followed by Dunnett’s multiple
comparison test using GraphPad Prism software version
5.0 (GraphPad Software Inc., CA, USA). The data were
expressed as Mean ± Standard Error (SE).
Results
Effect of OA-F2 on Knee diameter, Paw volume and Paw
latency in CIOA rats
OAC group demonstrated a significant increase in joint
diameter (p < 0.01) (Fig. 1). Both DICLO (p < 0.01) and
OA-F2 treated group substantially attenuated the in-
crease in joint diameter. Treatment with OA-F2L, M
and H showed 25%, 88% (p < 0.01) and 89% (p < 0.01) re-
duction in joint swelling, respectively (Fig. 1). DICLO
produced considerable inhibition in the paw edema by
29.83 ± 1.33% (Fig. 2). Groups OA-F2L, M and H pro-
duced 28.02 ± 2.58%, 24.19 ± 3.50% and 22.48 ± 1.01%
inhibition of paw edema, respectively (Fig. 2), which
shows OA-F2 has anti-inflammatory effect. OA-F2L,
OA-F2M (p < 0.01), OA-F2H and DICLO (p < 0.01)
showed considerable increase in right paw withdrawal
latency compared to OAC (Fig. 3).
Effect of OA-F2 on serum CRP, ALP and GAG levels in
CIOA rats
As a result of inflammation induced by collagenase in-
jection, the levels of CRP, ALP and GAG were increased
in all OA control rats. Elevated levels of CRP in OA have
been correlated with disease progression [24]. Serum
CRP levels were significantly decreased by OA-F2L (p <
0.001) and OA-F2M compared to OAC (Fig. 4). In OA,
ALP levels increases in the serum [25]. OA-F2L, M and
H significantly (p < 0.001) decreased ALP compared to
OAC (Fig. 5). Proteoglycans consist of a protein core
with GAG side chains. During inflammation and
Fig. 2 Effect of OA-F2 on percent inhibition of paw edema. Values
are expressed as Mean ± SE; n = 6. DICLO: Positive control, OA-F2L:
OA-F2 at 135 mg/kg b. wt., OA-F2M: OA-F2 at 270 mg/kg b. wt.,
OA-F2H: OA-F2 at 540 mg/kg b. wt
Fig. 1 Effect of OA-F2 on knee swelling. Values are expressed as
Mean ± SE; n = 6. **p < 0.01 compared to OAC. #p < 0.05, ##p < 0.01
compared to DICLO. Data were analyzed by One-Way ANOVA
followed by the Dunnett’s multiple comparison test. OAC: Osteoarthritic
control, DICLO: Positive control, OA-F2L: OA-F2 at 135 mg/kg b. wt.,
OA-F2M: OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
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cartilage degradation, GAG monomers are released,
which can be detected in synovial fluid and even in
blood serum serving as the clinical parameter of OA
[26]. Serum GAG levels were significantly increased in
OAC group compared to HC (p < 0.001) (Fig. 6). DICLO
(p < 0.05), OA-F2L (p < 0.001), OA-F2M (p < 0.001) and
OA-F2H (p < 0.001) have significantly decreased GAG
levels compared to OAC (Fig. 6).
Radiography and Histopathology evaluation of rat knee
joint
Radiographic images of the joints were compared be-
tween the right knee (induced) and left knee for erosion
of articular cartilage, reduced joint space and osteophyte
formation. The induced knee in OAC group showed
severe osteoarthritic changes, such as marked erosion of
articular cartilage and reduction in joint space due to
loss of articular cartilage (Fig. 7b). In HC group, the
patello-femoral joints of the knee appeared normal with-
out obvious abnormalities in surrounding tissue (Fig. 7a).
DICLO treated group showed severe changes of OA
(Fig. 7c). In the OA-F2L group, joint space was found
protected with no signs of erosions at articular surface
(Fig. 7d). Regression in erosions of articular surface was
also seen in rats treated with OA-F2M (Fig. 7e) and joint
space in the knee joint was improved after treatment
with OA-F2H (Fig. 7f ). Thus, OA-F2 appeared to pos-
sess cartilage protection abilities.
Histology of the synovium in HC group showed 1–2
layers of cells without cellular infiltration (Fig. 8a1). In
OAC group, lining cells showed mild increase in layer
and stroma showed mononuclear infiltrate (Fig. 8a2).
Compared to DICLO, OA-F2L and OA-F2H have shown
protection to synovium. Histology of the articular cartil-
age in HC group showed cartilage with normal volume,
smooth resilient surface with all distinguishable zones
intact (Fig. 8b1). Chondrocyte pathology was within nor-
mal limits (Fig. 8c1) and the matrix was densely stained
red with Safranin (Fig. 8d1). Intra-articular injection of
collagenase produced erosion of cartilage with irregular
surface and fibrillation, chondrocytes were seen in clus-
ters in joint tissues of OAC and DICLO (Fig. 8c2, c3).
As compared with control group (HC), proteoglycans
(PGs) integrity was found decreased in the upper cartil-
age zone (Fig. 8d2, d3). Comparatively, treatment with
OA-F2L and M has prevented cartilage degradation.
OA-F2 also has shown more collagen deposition with
reduced cleft formation compared to OAC and DICLO
(Fig. 8c4, c6). PGs layer density was also increased after
the OA-F2 treatment, compared to OAC and DICLO
(Fig. 8d4, d6). Thus, OA-F2 protected chondroid matrix
as well as prevented cartilage surface degeneration.
Figure 8e1 to e6 (H and E staining) gives an overview of
the whole joint at low magnification.
Effect of OA-F2 on expression of anti-oxidant genes,
MMPs and TIMP in CIOA rats
Osteoarthritic control rats showed down-regulation of
SOD, GPx and CAT in the knee joint synovium by
~1.22-fold, ~1.22-fold and ~1.33-fold, respectively com-
pared to control rats (Figs. 9 and 10). On the contrary,
osteoarthritic rats receiving OA-F2L, M and H, showed
up-regulation in the synovial expression of SOD by
Fig. 4 Effect of OA-F2 on CRP levels in the serum. Values are
expressed as difference in Mean ± SE between before (13th day)
and after (34th day) treatment; n = 6. ***p < 0.001 compared to OAC.
#p < 0.05, ###p < 0.001 compared to DICLO. Data were analyzed by
One-Way ANOVA followed by Dunnett's multiple comparison test.
HC: Healthy control, OAC: Osteoarthritic control, DICLO: Positive
control, OA-F2L: OA-F2 at 135 mg/kg b. wt., OA-F2M: OA-F2 at
270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
Fig. 3 Effect of OA-F2 on paw latency. Values are presented in
Mean ± SE; n = 6. **p < 0.01 compared to OAC. #p < 0.05, ##p < 0.01
compared to DICLO. Data were analyzed by One-Way ANOVA
followed by Dunnett’s multiple comparison test. OAC: Osteoarthritic
control, DICLO: Positive control, OA-F2L: OA-F2 at 135 mg/kg b. wt.,
OA-F2M: OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg
b. wt
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~1.87-fold (p < 0.01), ~1.22-fold and ~1.29-fold, respect-
ively compared to osteoarthritic control rats (Fig. 9).
GPx expression was also elevated by ~2.51-fold (p <
0.01), ~1.36-fold and ~1.22-fold in osteoarthritic rats
receiving OA-F2L, M and H, respectively (Fig. 9). Simi-
larly, Up-regulation in the CAT expression by ~1.29-fold
and ~1.15-fold, respectively was also observed in osteo-
arthritic rats receiving OA-F2M and H compared to
osteoarthritic control rats (Fig. 10). OA-F2L did not
show up-regulation in CAT expression. Rats receiving
DICLO did not show any up-regulation in SOD, GPx or
CAT expression. In the knee synovium, osteoarthritic
control rats revealed up-regulation of MMP-3, MMP-9
and TIMP-1 by ~9.34-fold (p < 0.05), ~33.47-fold and
~1.57-fold when compared to control rats (Figs. 11 and
12). Significant down-regulation in expression of MMP-
3 by ~4.45-fold (p < 0.05), ~8.55-fold (p < 0.01), ~3.58-
fold (p < 0.05) and ~4.29-fold (p < 0.05) was observed in
the osteoarthritic rats receiving OA-F2L, M, H and
DICLO respectively (Fig. 11), compared to osteoarthritic
control rats. These groups also showed down-regulation
of MMP9 expression by ~7.85-fold, ~25.50-fold, ~19.38-
fold and ~27.47-fold, respectively (Fig. 11). Up-
regulation of TIMP-1 was observed in rats treated with
OA-F2L, H and DICLO by ~1.52-fold, ~1.17-fold and
~1.02-fold, respectively when compared to osteoarthritic
control rats (Fig. 12). OA-F2M was unable to modulate
the level of synovial TIMP-1 in the osteoarthritic
knee joints.
Discussion
Osteoarthritis (OA) is a major cause of disability
throughout the world, it causes pain due to inflamed
knee joints, which involves progressive degeneration of
articular cartilage, synovitis, formation of osteophyte,
increased fibrillation due to increased denaturation and
loss of collagen fibers [27]. Current therapeutic options
for OA are mainly palliative and have little influence on
progression of the disease and are also associated with
many adverse effects [28]. Therefore, there is an increas-
ing merit in use of compounds derived from natural
plants or herbs for the treatment of OA [28]. In OA,
cartilage degeneration is the result of combined bio-
chemical and mechanical factors. Therefore, restoration
of MMP-TIMP balance with the help of natural products
that can effectively control oxidative stress and inflam-
mation may provide an important therapeutic approach
for the treatment of OA [29].
Intra-articular injection of collagenase significantly
increased inflammation and swelling of the knee joint
and thus increased diameter of the knee. Oral admin-
istration of OA-F2 significantly attenuated this inflam-
mation and has reduced knee swelling and paw
edema compared to osteoarthritic control group
(Figs. 1 and 2). MMPs are the catalytic enzymes,
which degrade the cartilage and in turn enhance the
inflammatory process by releasing more cytokines and
Fig. 5 Effect of OA-F2 on ALP levels in the serum. Values are expressed as Mean ± SE; n = 6. ***p < 0.001 compared to OAC. #p < 0.05, ###p < 0.001
compared to DICLO. Data were analyzed by One-Way ANOVA followed by Dunnett’s multiple comparison test. OAC: Osteoarthritic control, DICLO:
Positive control, OA-F2L: OA-F2 at 135 mg/kg b. wt., OA-F2M: OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
Fig. 6 Effect of OA-F2 on GAG release in the serum. Values are
expressed as difference in Mean ± SE between before (13th day) and
after (34th day) treatment; n = 6. *p < 0.05; ***p < 0.001 compared to
OAC. #p < 0.05; ##p < 0.01; ###p < 0.001 compared to DICLO. Data
were analyzed by One-Way ANOVA followed by Dunnett’s multiple
comparison test. HC: Healthy control, OAC: Osteoarthritic control,
DICLO: Positive control, OA-F2L: OA-F2 at 135 mg/kg b. wt., OA-F2M:
OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
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MMPs [27]. OA-F2 treatment to osteoarthritic rats
showed significant improvement in paw withdrawal
latency time compared to untreated osteoarthritic rats
(Fig. 3). Serum CRP, probably the most widely used
clinical marker of systemic inflammation, has been
shown to correlate well with CRP in synovial fluid in
patients with OA or RA [30]. In OA patients, ele-
vated levels of CRP and ALP were recorded [25, 31].
Interestingly in the present study, CRP and ALP
levels were significantly decreased by OA-F2 as com-
pared to osteoarthritic control and diclofenac treated
group (Figs. 4 and 5). Glycosaminoglycan is a major
component of joint cartilage, joint fluid and other soft
connective tissues. GAGs are released from the degrading
cartilage matrix in a large amount. Administration of OA-
F2, lowered GAG release in which means cartilage is pro-
tected as seen in the improved parameter of the joint
space (Figs. 6 and 7), which was also confirmed in radiog-
raphy. H and E staining showed that OA-F2 protected
synovium and cartilage degeneration during OA (Fig. 8).
Modification of ECM and increased articular chondrocyte
proliferation are characteristics of OA [32], OA-F2 also
protected chondroid matrix and prevented proteoglycan
loss from ECM (Fig. 8). Histopathological observation
suggests correlation of OA-F2 intervention with improved
muscle degeneration, fibrillation, erosion of cartilage and
chondroid matrix.
As observed in histopathology, studied biochemical
and physiological parameters, deteriorating changes
seen in OA induced rats are may be outcomes of ele-
vated release of MMPs or these focal changes are
might be due to secretion of pro-inflammatory cyto-
kines with reactive oxygen species (ROS) from the
inflamed synovium and from activated chondrocytes
[27, 29]. ROS are also involved in the regulation of
IL-1 effects mediated by NF-κB. In the progression of
OA, NF-κB is a transcriptional factor that can be
triggered by a number of stimuli, such as cytokines,
excessive mechanical stress and degradation products
of ECM [28]. Activated NF-κB regulates several cata-
bolic enzymes involved in matrix degradation, includ-
ing MMPs [28, 33]. MMP-3 has been shown to break
down a number of ECM proteins, including fibronec-
tin, laminin, denatured collagens and proteoglycans
[28]. In addition to ECM degradation, MMP-3 is in-
volved in the activation cascades of MMP-13 and
gelatinases [28]. Since MMP-1 and MMP-3 play vital
roles in ECM turnover, their regulation has been sug-
gested to be useful therapeutic target [28]. On the
other hand, TIMPs are the endogenous regulators of
MMPs, which play important roles in maintaining
homoeostasis with MMPs [28]. Imbalance between
MMPs and TIMPs is a salient feature of OA progres-
sion, leading to disruption of the balance between
Fig. 7 Right knee joint radiographs (in the Anterior Posterior view) of control and experimental animals. All radiographs were taken keeping
object to x-ray source distance constant (100 cm) and scale is showing extent of zoom. a Saline injected groups showed smooth articular surface
(arrow) while in (b) OAC and (c) DICLO group showed severe changes of OA; Comparatively (d) OA-F2L, (e) OA-F2M and (f) OA-F2H group showed
minimal changes of OA
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ECM biosynthesis and degradation [28]. Therefore,
exploration of the mechanisms through which the
proteolytic activity, production and expression of
MMPs are inhibited by plant-derived natural products
may lead to new therapeutic strategies [34]. To deter-
mine whether OA-F2 may affect the destruction of
articular cartilage, we examined the expression of the
OA biomarkers MMP-3, MMP-9 and TIMP-1 in the
synovium of collagenase-induced OA rats. Interest-
ingly, our results demonstrated that the elevated
MMP-3 and −9 expression in osteoarthritic control
rats were decreased by OA-F2 supplementation.
Fig. 8 Histopathology pictures of synovial membrane and cartilage. First column (a1-6) showing photographs of synovium stained with H and E
and further are photographs of cartilage stained with H and E (b1-6), Masson’s trichome (c1-6) and safranin-O (d1-6) respectively. Last column
(e1-6) showing photographs of whole knee joint stained with H and E. HC: Healthy control, OAC: Osteoarthritic control, DICLO: Positive control,
OA-F2L: OA-F2 at 135 mg/kg b. wt., OA-F2M: OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt., H and E: hematoxyline and eosin
Fig. 9 Effect of OA-F2 on the mRNA expression of SOD-1 and GPx-1 in the synovium of rats. Values are expressed as Mean ± SE (n = 3). Comparisons
were done between OAC/HC and each individual treated group by Dunnett’s multiple comparison test. **p < 0.01 Compared to OAC.
#p < 0.05 compared to HC. HC: Healthy control, OAC: Osteoarthritic control, DICLO: Positive control, OA-F2L: OA-F2 at 135 mg/kg b. wt.,
OA-F2M: OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
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Present results demonstrated up-regulation of TIMP-1
by OA-F2L and OA-F2H in osteoarthritic rats. S. cor-
difolia extract was shown to inhibit COX enzyme and
prostaglandin synthesis [11], whereas, Z. officinale
decrease IL1, NO and PGE2 and LTB4 production as
well as inhibit TNF-α production [11, 13, 14].
In summary, we evaluated the efficacy of orally admin-
istered OA-F2, a composition containing a blend of two
medicinal plants, roots of S. cordifolia and rhizomes of
Z. officinale, in collagenase induced OA model in rats.
OA-F2 notably tackled the physiological problems and
decreased levels of inflammatory markers such as CRP,
ALP and GAG in the serum. We demonstrated at the
mRNA level that OA-F2 inhibited the expression of
MMP −3 and −9 and increased the expression of TIMP-
1, all of which are classical biomarkers of inflammation
and cartilage degradation in OA.
Conclusions
Our study revealed chondroprotective effect of OA-F2,
which is explained through modulation of biochemical
parameters studied as well as expression of MMPs-
TIMP genes in knee synovial tissue. OA-F2 thus merits
consideration as an alternative therapy from natural
sources for the treatment of OA. However, further
preclinical and human clinical studies are necessary.
Fig. 12 Effect of OA-F2 on the mRNA expression of TIMP1 in the
synovium of rats. Values are expressed as Mean ± SE (n= 3). Comparisons
were done between OAC/HC and each individual treated group
by Dunnett’s multiple comparison test. #p < 0.05 compared to
HC. HC: Healthy control, OAC: Osteoarthritic control, DICLO: Positive
control, OA-F2L: OA-F2 at 135 mg/kg b. wt., OA-F2M: OA-F2 at
270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
Fig. 10 Effect of OA-F2 on the mRNA expression of CAT in the
synovium of rats. Values are expressed as Mean ± SE (n = 3). HC:
Healthy control, OAC: Osteoarthritic control, DICLO: Positive control,
OA-F2L: OA-F2 at 135 mg/kg b. wt., OA-F2M: OA-F2 at 270 mg/kg b.
wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
Fig. 11 Effect of OA-F2 on the mRNA expression of MMP3 and MMP9 in the synovium of rats. Values are expressed as Mean ± SE (n = 3).
Comparisons were done between OAC/HC and each individual treated group by Dunnett’s multiple comparison test. *p < 0.05; **p < 0.01
Compared to OAC. #p < 0.05 compared to HC. HC: Healthy control, OAC: Osteoarthritic control, DICLO: Positive control, OA-F2L: OA-F2 at
135 mg/kg b. wt., OA-F2M: OA-F2 at 270 mg/kg b. wt., OA-F2H: OA-F2 at 540 mg/kg b. wt
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